YIDU TECH Achieves First Full-Year Profit in FY 2026, Exceeding Guidance

Stock News
Yesterday

China's leading AI healthcare company, YIDU TECH (02158), held its FY 2026 results briefing on July 2nd, detailing its annual performance for the period ended March 31, 2026. The company reported its first-ever full-year profit, with an annual profit reaching RMB 78.8 million, surpassing the upper end of its previously announced profit forecast range of RMB 55-70 million.

Net profit attributable to owners reached RMB 72.7 million, approximately 30% higher than the top end of the corresponding forecast range of RMB 56 million. The company's total annual revenue grew 14.6% year-over-year to RMB 820 million, while adjusted EBITDA surged more than 4.6 times to RMB 220 million.

Profitability metrics also improved, with the overall gross profit margin rising to 36.4% from 33.5% in the prior year. Net cash flow from operating activities turned positive in the second half of the fiscal year, recording RMB 29.3 million, indicating the company's profitability is on an upward trajectory.

In terms of growth drivers, the company's core segments showed strong performance in new order intake. New orders for the AI for Medical segment grew by 22.3% year-over-year, while new orders for the AI for Life Sciences segment increased by 42% year-over-year, providing clear visibility for future revenue growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10